BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 4282801)

  • 41. [Biological bases of tissue synthesis using human fibrin glue].
    Pini Prato GP; Cortellini P; Clauser C; Guazzini S
    Minerva Stomatol; 1983; 32(6):903-14. PubMed ID: 6199658
    [No Abstract]   [Full Text] [Related]  

  • 42. Potentiation of the anti-factor VIII effect of thrombin in plasma by the plasminolytic derivatives of fibrinogen and fibrin.
    Chandra S; Triantaphyllopoulos DC
    Thromb Diath Haemorrh; 1973 Nov; 30(2):235-47. PubMed ID: 4272616
    [No Abstract]   [Full Text] [Related]  

  • 43. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations.
    Francis CW; Marder VJ
    Blood; 1988 May; 71(5):1361-5. PubMed ID: 2965927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Wound-healing disorders and infections in the oral cavity due to fibrinolysis. An experimental study].
    Edinger D; Tilsner V
    Dtsch Z Mund Kiefer Gesichtschir; 1984; 8(1):50-3. PubMed ID: 6335415
    [No Abstract]   [Full Text] [Related]  

  • 45. [Fibrinogen and fibrin split products and their biological importance].
    Krantz S; Fiedler H; Lober M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 96(1):1-13. PubMed ID: 4110779
    [No Abstract]   [Full Text] [Related]  

  • 46. The relationship of fibrinogen structure to plasminogen activation and plasmin activity during fibrinolysis.
    Lucas MA; Fretto LJ; McKee PA
    Ann N Y Acad Sci; 1983 Jun; 408():71-91. PubMed ID: 6223562
    [No Abstract]   [Full Text] [Related]  

  • 47. Human factor XIII: fibrin-stabilizing factor.
    Lorand L; Losowsky MS; Miloszewski KJ
    Prog Hemost Thromb; 1980; 5():245-90. PubMed ID: 7422874
    [No Abstract]   [Full Text] [Related]  

  • 48. Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays.
    Arnesen H
    J Oslo City Hosp; 1977 Jun; 27(6):69-80. PubMed ID: 142131
    [No Abstract]   [Full Text] [Related]  

  • 49. Hereditary dysfibrinogenemia.
    Bithell TC
    Clin Chem; 1985 Apr; 31(4):509-16. PubMed ID: 3978780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Fibrinogen and its related substances (author's transl)].
    Matsuda M
    Rinsho Ketsueki; 1977 Sep; 18(9):1065-81. PubMed ID: 338951
    [No Abstract]   [Full Text] [Related]  

  • 51. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 52. Fibrinogen and FDP-models of molecular pathology?
    Gaffney PJ
    Br J Haematol; 1973 Aug; 25(2):271-2. PubMed ID: 4269481
    [No Abstract]   [Full Text] [Related]  

  • 53. Structural organization of the fibrinogen macromolecule related to the process of fibrin formation.
    Velican D
    Rev Roum Med Intern; 1972; 9(5):419-36. PubMed ID: 4576978
    [No Abstract]   [Full Text] [Related]  

  • 54. Cross-linking of salmon fibrinogen and fibrin by factor XIII and transglutaminase.
    Murtaugh PA; Halver JE; Gladner JA
    Biochem Biophys Res Commun; 1973 Oct; 54(3):849-55. PubMed ID: 4148128
    [No Abstract]   [Full Text] [Related]  

  • 55. Cross-linking of fibrin by fibrin=stabilizing factor.
    McKee PA; Schwartz ML; Pizzo SV; Hill RL
    Ann N Y Acad Sci; 1972 Dec; 202():127-48. PubMed ID: 4565368
    [No Abstract]   [Full Text] [Related]  

  • 56. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
    Brown CH; Crowe MF
    J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative studies on fibrin formation and effects of dextran.
    Muzaffar TZ; Stalker AL; Bryce WA; Dhall DP; Smith G
    Bibl Anat; 1973; 12():340-4. PubMed ID: 4790370
    [No Abstract]   [Full Text] [Related]  

  • 58. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
    Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
    Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparison of growth of Staphylococcus aureus in a fibrin-clotting system and in clotted blood - a quantitative investigation (author's transl)].
    Stanek G; Bösch P; Weber P
    Zentralbl Bakteriol Orig A; 1978 Jun; 240(4):441-6. PubMed ID: 696057
    [No Abstract]   [Full Text] [Related]  

  • 60. [From fibrinogen to fibrin and its dissolution].
    Juhan-Vague I; Hans M
    Bull Acad Natl Med; 2003; 187(1):69-82; discussion 83-4. PubMed ID: 14556455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.